The Expression Profile of the RANK/RANKL/OPG Pathway in Breast Cancer Stem Cells Isolated From Breast Cancer Cell...

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• The RANK/RANKL/OPG signaling pathway is implicated in breast cancer progression and metastasis.
• The role and expression patterns of this pathway in breast cancer stem cells (BCSCs) are not well understood.
• BCSCs are critical drivers of tumor growth, metastasis, and therapeutic resistance.

Purpose of the Study:

• To characterize the expression profile of the RANK/RANKL/OPG axis in BCSCs.
• To compare pathway expression in BCSCs derived from MDA-MB-231 (triple-negative) and MCF-7 (hormone-receptor-positive) cell lines.
• To investigate the relationship between RANK/RANKL/OPG signaling and stemness markers in BCSCs.

Main Methods:

• Generation of mammospheres (MS) to enrich for BCSCs from MDA-MB-231 and MCF-7 cell lines.
• Flow cytometry to analyze CD44+/CD24- subpopulations, a marker for BCSCs.
• Quantitative PCR and Western blotting to assess the expression of stemness markers (OCT4, SOX2) and the RANK/RANKL/OPG axis components (RANK, OPG, RUNX2).

Main Results:

• Mammospheres showed enrichment of CD44+/CD24- cells and upregulation of stemness markers OCT4 and SOX2, with higher expression in MDA-MB-231 derived MS.
• RANK expression was significantly upregulated in MDA-MB-231 MS but not in MCF-7 MS.
• OPG mRNA was elevated in MS from both cell lines, but secreted OPG protein was paradoxically reduced. RUNX2 expression decreased in MS compared to adherent cells.

Conclusions:

• The RANK/RANKL/OPG pathway exhibits complex and differential regulation in BCSCs, varying by cell line context.
• These findings suggest a potential role for this pathway's dysregulation in the aggressive phenotype and metastatic potential of triple-negative breast cancer.
• Further elucidation of the OPG/RANK/RANKL axis in BCSCs is warranted to understand its full implications in breast cancer.